These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4387 related articles for article (PubMed ID: 28838390)

  • 1. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.
    Russo A; Russano M; Franchina T; Migliorino MR; Aprile G; Mansueto G; Berruti A; Falcone A; Aieta M; Gelibter A; Russo A; Barni S; Maio M; Martelli O; Pantano F; Iacono D; Calvetti L; Quadrini S; Roca E; Vasile E; Imperatori M; Occhipinti M; Galvano A; Petrelli F; Calabrò L; Pasquini G; Intagliata S; Ricciardi GRR; Tonini G; Santini D; Adamo V
    Adv Ther; 2020 Mar; 37(3):1145-1155. PubMed ID: 32002809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
    Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.
    Guo D; Li M; Chen D; Jing W; Zhu H; Fu L; Kong L; Yue J; Yu J
    Future Oncol; 2019 Feb; 15(6):625-635. PubMed ID: 30430864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
    Shao N; Cai Q
    Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Impact of the Pretreatment or Posttreatment NLR and PLR on the Response of First Line Chemotherapy and the Outcomes in Patients with Advanced Non-small Cell Lung Cancer].
    Yi F; Gu Y; Chen S; Liu Y; Yin W; Zhang Y; Cao B
    Zhongguo Fei Ai Za Zhi; 2018 Jun; 21(6):481-492. PubMed ID: 29945708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Yılmaz U; Ozdemir O; Batum O; Ermin S
    Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
    Miao Y; Yan Q; Li S; Li B; Feng Y
    Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer.
    Zhang H; Xia H; Zhang L; Zhang B; Yue D; Wang C
    Am J Surg; 2015 Sep; 210(3):526-35. PubMed ID: 26105800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of neutrophil-to lymphocyte ratio and platelet-to lymphocyte ratio in older patients with metastatic colorectal cancer.
    Cruz-Ramos M; Del Puerto-Nevado L; Zheng B; López-Bajo R; Cebrian A; Rodríguez-Remirez M; García-García L; Solanes-Casado S; García-Foncillas J
    J Geriatr Oncol; 2019 Sep; 10(5):742-748. PubMed ID: 30327283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer.
    Kiriu T; Yamamoto M; Nagano T; Hazama D; Sekiya R; Katsurada M; Tamura D; Tachihara M; Kobayashi K; Nishimura Y
    PLoS One; 2018; 13(2):e0193018. PubMed ID: 29447258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio, and Platelets in the Prognosis of Metastatic Renal Cell Carcinoma.
    Huszno J; Kolosza Z; Mrochem-Kwarciak J; Rutkowski T; Skladowski K
    Oncology; 2019; 97(1):7-17. PubMed ID: 31048577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer.
    Liu D; Jin J; Zhang L; Li L; Song J; Li W
    Cell Physiol Biochem; 2018; 46(4):1595-1605. PubMed ID: 29694985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of neutrophil-lymphocyteratio/platelet-lymphocyteratioin lung cancers: a meta-analysis.
    Yang HB; Xing M; Ma LN; Feng LX; Yu Z
    Oncotarget; 2016 Nov; 7(47):76769-76778. PubMed ID: 27732958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
    Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
    J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer: Results from a large cohort.
    Yuan C; Li N; Mao X; Liu Z; Ou W; Wang SY
    Thorac Cancer; 2017 Jul; 8(4):350-358. PubMed ID: 28544400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 220.